ライフサイエンスコーパス: red cell transfusion

1 cause of transfusion-related mortality with red cell transfusion.

2 RDS risk and mortality including the role of red cell transfusion.

3 raventricular hemorrhage and need for packed red cell transfusion.

4 d significantly higher rates of bleeding and red-cell transfusion.

5 as the percentage of patients who received a red-cell transfusion.

6 east 2 g per deciliter from baseline without red-cell transfusion.

7 east 2 g per deciliter from baseline without red-cell transfusion.

8 o, 1.91; 95% confidence interval, 1.49-2.44) red cell transfusions.

9 er entry effectively decreased inappropriate red cell transfusions.

10 nd early death in patients receiving regular red cell transfusions.

11 nt recovery, and received fewer platelet and red cell transfusions.

12 ronic kidney disease may reduce the need for red cell transfusions.

13 not effective generally become dependent on red-cell transfusions.

14 ents, spleen response, and independence from red-cell transfusions.

15 sion-dependent beta-thalassemia need regular red-cell transfusions.

16 tin (epoetin alfa) might reduce the need for red-cell transfusions.

17 ate kinase deficiency who were not receiving red-cell transfusions.

18 ive vasopressor infusions (66.6% vs. 57.8%), red-cell transfusions (13.6% vs. 7.0%), and dobutamine (

19 combination also increased the need for any red cell transfusion (87 of 9,152 [1.0%] vs. 44 of 9,126

20 e standard, autologous, leukoreduced, packed red cell transfusion after 1, 2, 3, 4, 5, or 6 weeks of

21 poetin alfa does not reduce the incidence of red-cell transfusion among critically ill patients, but

22 verse event rates associated with IV iron vs red cell transfusion and discuss using first-line IV iro

23 l failure have greatly reduced the number of red cell transfusions and hence the propensity to iron o

24 y been limited to supportive care, including red cell transfusions and splenectomy.

25 o identify patients who are at high risk for red cell transfusions and therefore most likely to benef

26 Secondary outcomes included red-cell transfusion and other clinical outcomes.

27 ter); 3 of them were previously dependent on red-cell transfusions and no longer needed transfusions.

28 of intravenous fluids, vasoactive drugs, and red-cell transfusions and reflected by significantly wor

29 sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refra

30 Red cell transfusions are associated with the developmen

31 estrictive threshold for hemoglobin level in red-cell transfusions, as compared with a liberal thresh

32 ed within 48 hours after delivery to receive red-cell transfusions at higher or lower hemoglobin thre

33 estimated blood loss greater than 1000 ml or red-cell transfusion by day 2 than placebo, but it did n

34 nces in the proportion of patients requiring red cell transfusions, changes in quality of life, or th

35 A-DR15, younger age, and shorter duration of red cell transfusion dependence as pretreatment variable

36 ent revision include stricter definitions of red cell transfusion dependency and independency and con

37 t infants, a higher hemoglobin threshold for red-cell transfusion did not improve survival without ne

38 We examined data from patients given red-cell transfusions during coronary-artery bypass graf

39 level of 9 g per deciliter or higher without red-cell transfusion for at least 12 consecutive months.

40 oglobin level of >=9 g per deciliter without red-cell transfusions for >=12 months).

41 emoglobin level of 9 g per deciliter without red-cell transfusions for 12 months).

42 Jakob disease have been identified following red cell transfusions from donors who subsequently devel

43 ty and compliance with each of inotropes and red cell transfusions, glucocorticoids, and lung-protect

44 Whereas restrictive red cell transfusion has become a standard of care for t

45 ped an evidence-based decision algorithm for red cell transfusion in adult intensive care units.

46 esearch has focused on controlled studies of red cell transfusion in specific clinical settings.

47 otocol and computerized decision support for red cell transfusion in the critically ill.

48 ique, reduces the requirement for allogeneic red cell transfusions in patients undergoing major hepat

49 e administration, requirement for allogeneic red cell transfusion, intercostal catheter drainage at 4

50 iology of SCD is better understood; however, red cell transfusion is currently the most studied and a

51 Restrictive red cell transfusion is recommended to minimize risk ass

52 hemoglobin threshold at which postoperative red-cell transfusion is warranted is controversial.

53 uggest that higher hemoglobin thresholds for red-cell transfusions may reduce the risk of cognitive d

54 Red-cell transfusion occurred in 52.3% of the patients i

55 was associated with decreased likelihood of red cell transfusion (odds ratio, 0.43; 95% confidence i

56 e criteria do not include treatments such as red cell transfusion or surgical interventions performed

57 01) and platelet (P =.01) recovery and fewer red cell transfusions (P =.02) than 48 historical contro

58 The mean number of red cell transfusions per intensive care unit admission

59 Although restrictive red cell transfusion practice has become a standard of c

60 current criteria for blood donation preserve red cell transfusion quality for the recipient and prote

61 of blood donation-induced iron deficiency on red cell transfusion quality or donor cognition are unkn

62 =800 mL, ANH reduced not only the allogeneic red cell transfusion rate (18.2% vs. 42.4%, P = 0.045) b

63 ANH reduced the overall allogeneic red cell transfusion rate by 50% compared with STD.

64 reutzfeldt-Jakob disease and an asymptomatic red cell transfusion recipient, who did not die of varia

65 either the number of patients who received a red-cell transfusion (relative risk for the epoetin alfa

66 tients who received G-CSF + EPO had a higher red cell transfusion requirement (median, 161.0 mL/kg) t

67 rfarin resulted in faster reversal and lower red cell transfusion requirement with fewer adverse even

68 ary end point was the effect of EPO on total red cell transfusion requirements during induction thera

69 s, complexity of operation, or perioperative red cell transfusion requirements.

70 mpare outcomes of a restrictive to a liberal red cell transfusion strategy in 20% or more total body

71 ients with AMI, the panel suggests a liberal red cell transfusion strategy when the hemoglobin concen

72 The effect of a liberal red-cell transfusion strategy as compared with a restric

73 The effect of a restrictive versus liberal red-cell transfusion strategy on clinical outcomes in pa

74 those in the G-CSF + EPO group received more red cell transfusions than did those given G-CSF alone (

75 of at least 12 g per deciliter, each without red-cell transfusion; the primary end point for the seco

76 eath after cardiac surgery) to a restrictive red-cell transfusion threshold (transfuse if hemoglobin

77 g from induction of anesthesia) or a liberal red-cell transfusion threshold (transfuse if hemoglobin

78 we randomly assigned patients who required a red-cell transfusion to receive blood that had been stor

79 al, we randomly assigned patients undergoing red-cell transfusion to receive units of red cells from

80 sideroblasts who had been receiving regular red-cell transfusions to receive either luspatercept (at

81 Mean red cell transfusion was 3.2 with frozen plasma and 1.4

82 ovided to the 1098 participants who received red-cell transfusion was 7 days in the shorter-term stor

83 for death, a restrictive strategy regarding red-cell transfusion was noninferior to a liberal strate

84 verity of renal and hepatic dysfunction, and red cell transfusions were all independent risk factors

85 Red-cell transfusions were administered to 297 patients

86 in the critically ill, is often treated with red-cell transfusions, which are associated with poor cl

87 plasma hemoglobin increase immediately after red cell transfusion, with more significant increases ob

88 urs after start of surgery, and avoidance of red cell transfusions within 24 hours after start of sur

89 od loss greater than 1000 ml or receipt of a red-cell transfusion within 2 days after delivery.